Insights into the Diversity in Dermatology Clinical Trials

A review article published online by JAMA Dermatology attempts to improve our understanding of the racial and ethnic makeup of participants in randomized clinical trials of common dermatologic conditions. Arash Mostaghimi of Brigham & Women's Hospital and Harvard Medical School, Boston, and coauthors analyzed 626 articles reporting randomized clinical trials for acne, psoriasis, atopic dermatitis and eczema, vitiligo, alopecia areata, seborrheic dermatitis and lichen planus because the conditions are common and lack specific racial predilection.

Of the 626 articles, 97 studies were exclusively conducted in the United States and 164 were partially conducted in the United States; 58 of the 97 studies conducted exclusively within the United States reported on the racial and ethnic demographics of study participants.

Among those 58 studies conducted exclusively within the United States that recorded race/ethnicity, 74.4% of the 13,681 participants were white. Among these studies, 46 noted racial categories other than white and nonwhite for a total of 11,140 participants, of whom 72% where white, 13% were African American, 14.7% were recorded as Hispanic and 3.3% were recorded as Asian.

"While those trials that fully characterized race achieved recruitment of a proportional number of African American participants (compared with the U.S. population at 13%), those same trials did not achieve such proportionality with respect to ethnicity. Although 17% of the population identifies as Hispanic by ethnicity, only 14.7% of participants in those same studies identified ethnically as Hispanic. Moreover, the dearth of full reporting of ethnicity and race suggests that the actual racial and ethnic makeup of many studies may be decidedly more homogenous," according to the article.

Articles about eczema and acne were more likely to include more than 20% racially/ethnically diverse participants than psoriasis studies, the authors report.

The review concludes, "Journals and funding sources can reinforce our diverse clinical trial population by continuing to prioritize racial, ethnic, and genetic diversity within the articles they fund and publish; requiring reporting of racial and ethnic data in all dermatology RCTs will lead us even further. These combined efforts will enable dermatology to be an example within medicine for how to best achieve diversity within research and, by extension, clinical practice."

Advertisement

Source-Eurekalert